Oregon State University
Trial Pipeline
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
NCT07055854
Effect of Walnuts on Cognitive Function and Gut Microbiome in Older Adults
NCT06942351
Shift Worker Intervention for Sleep Health
NCT06384742
Optimizing Sleep Health in Nurses
NCT05965609
Almonds to Improve Gut Health and Decrease Inflammation
NCT05790564
Use of Empagliflozin to Treat Prediabetes
NCT05426525
Scalability of a Home Health Navigator Program to Reduce Arsenic, Nitrate, and Lead in Private Well Water
NCT05395663
Discovery of Biological Signatures for Cruciferous Vegetable Intake (Single Serving)
NCT04641026
Multi-site Animal Assisted Intervention for Children With DD and Their Family Dog
NCT04799119
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
NCT05482464
Mitochondrial Remodeling After Exercise
NCT04103424
Ultralow Dose PAH Binary Mixture Study
NCT03631667
Role of Centrum® Silver® in Improving Micronutrient Status in Older Men
NCT03004807
Benzo[a]Pyrene Ultralow Dose-Response Study
NCT03318978
Sensory Perception of Sweet Flavors in E-Cigarette
NCT03332953
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 4 | 1 |
What the Pipeline for Oregon State University Shows
According to the ClinicalTrials.gov registry, Oregon State University is linked to 42 US clinical trials across every stage of research activity. Of those, 31 studies are currently recruiting — about 74% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 14% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Oregon State University reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Oregon State University is Environmental Exposure with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.